1) The new issue of Nature Biotechnology carries an erratic editorial complaining that “alarmist” responses to the recent announcement that a project to synthesize an entire human genome may be launched “missed the point.” The editors say that worries about “synthetic life and secret meetings” missed the point. The lesser goals of the project—more “nearfetched,” if you will—call for synthesizing long, sub-genomic stretches of DNA that would, if successful, be tour de forces themselves and open a number of lines of important scientific inquiry. They list several, most of which appear ethical, with the possible exception of the potential to alter human stem cells with synthetic DNA. If the stem cells in question are somatic stem cells, I’d see no fundamental new ethical problem. If, however, the stem cells would be embryonic stem cells, more mature embryos, or even iPSCs, which could differentiate into germ cells in some settings, then I would say those experiments should not be done.
Moreover, the synthesis of a full Mycoplasma genome has been underproductive, stimulating less new research than it ought to have by now, they claim.
The editorial is erratic because at the end they write that although engendering live human offspring bearing synthetic genomes “is not the plan,” the editors nonetheless would be a “giant step” toward “the future that many people fear,” and that proposed “ultrasafe” approaches will do nothing to prevent the most dystopian attempts.
In the end, then, the Nature Biotechnology editors, in their density, make precisely the point that they claim the “alarmists” to have missed.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.